A Phase 3 interventional study of Selpercatinib and Cabozantinib in Medullary Thyroid Cancer, sponsored by Loxo Oncology, Inc.. Active, not recruiting at 143 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Carcinoma, Medullary with a site in China — 9 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Medullary · China.
Among the 18 studies in Carcinoma, Medullary with a site in China, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 5th registered.
144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.
Browse Carcinoma, Medullary studies →9 of the 18 studies in Carcinoma, Medullary with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Luo Yaping · Sites in China
Healthy volunteers
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 291 is above the median of 30 across 100 interventional studies indexed under Carcinoma, Medullary.
Median enrollment 151 across the 16 interventional studies, 260 across the 2 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Loxo Oncology, Inc., one of the names counted as Eli Lilly and Company. Under that name alone:
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Eli Lilly and Company has 5 studies filed under Carcinoma, Medullary — fewer than ten, so there is no comparison to draw.
3 of the studies in Carcinoma, Medullary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141369Shanghai Jiao Tong University School of MedicineTreatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | 2026-12-30 |
| NCT05830500Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | 2027-06 |
| NCT07649200ScinnoHub Pharmaceutical Co., Ltd.Study of SNH-118110 in Advanced Solid Tumors | 2027-06-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Carcinoma, Medullary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Adaptive sample size re-estimation will be performed at interim analysis. The sample size could be increased from approximately 250 to 400 depending on the results of interim analysis.
A defined/acceptable RET gene alteration identified in a tumor, germline deoxyribonucleic acid (DNA) or blood sample.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 milligrams Selpercatinib administered orally (PO) twice daily (BID). Adolescent Dose: 92 milligrams per square meter (mg/m2) BID (not to exceed 160 mg BID).
Drug: Selpercatinib
140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice. Cabozantinib Adolescent Dose: 40 mg/m2. Vandetanib Adolescent Dose: * 0.7 - \<0.9 - 100 mg every other day (QOD) * 0.9 - \<1.2 - 100 mg QD * 1.2 - \<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg * ≥1.6 - 200 QD
Drug: Cabozantinib · Drug: Vandetanib
Administered orally
Also known as: LY3527723, LOXO-292
Administered orally
Administered orally
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria, or death from any cause in the absence of BICR-documented progressive disease. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months
Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)
TFFS by BICR is defined as the time from randomization to the first occurrence of: * documented radiographic disease progression per RECIST 1.1 as assessed by BICR; or * unacceptable toxicity leading to treatment discontinuation as assessed by the investigator. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. To qualify as an event, the toxicity must be from an intolerable AE (defined as any study drug-related AE that meets protocol guidance for treatment discontinuation, with the exception of alopecia); or death (due to any cause).
Time frame: Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR
ORR is defined as the number of participants who achieved the best overall response (BOR) of CR or PR divided by the total number of participants randomized to each treatment arm. ORR per RECIST 1.1 as assessed by BICR.
Time frame: Baseline through Disease Progression or Death Up to 39 Months
Duration of Response (DoR) by BICR
DoR by BICR is defined as the time from the date that measurement criteria for complete response (CR) or partial response (PR) (whichever is first recorded) are first met by the BICR or investigator assessment, as applicable, until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 39 Months
Overall Survival (OS)
Overall survival (OS) is defined as the time from randomization until death from any cause. If the participant is alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.
Time frame: Baseline
PFS2 by Investigator
Progression-free survival 2 (PFS2) is defined as the time from randomization to disease progression (radiographic or symptomatic progression as determined by the investigator) on the next line of treatment or death from any cause in the absence of observed disease progression. If the participant is alive at the cutoff for analysis, and disease progression has not been observed, PFS2 data will be censored on the latest date of last progression-free assessment or start of the next line of treatment.
Time frame: Baseline
Comparative Tolerability: Number of Weeks With High Side Effect Bother Based Score of 3 or 4 on the Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5)
Comparative tolerability defined as a comparison of the proportion of time on treatment with high side effect bother as assessed by the FACT-GP5. The FACT-GP5 is a single question used to assess the overall bother of the treatment side effects. It is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bother from treatment side effects. Time with high side effect bother (i.e.) score of 3 or 4 is reported here and was derived as follows: cumulative amount of time, in weeks, during which a participant reports high side effect bother divided by the total duration of therapy (weeks), derived as (date of last study treatment dose - date of first study treatment dose + 1) divided by 7.
Time frame: Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause Up to 39 Months
The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement)
Time frame: Baseline
| Milestone | Selpercatinib - Treatment A (TRT A) | Cabozantinib or Vandetanib - Treatment B (TRT B) |
|---|---|---|
| Started | 193 | 98 |
| Received at least one dose of study drug | 193 | 97 |
| Completed | 18 | 56 |
| Not completed | 175 | 42 |
| Withdrew: On treatment | 175 | 40 |
| Withdrew: Withdrawal by subject | 0 | 2 |
PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria, or death from any cause in the absence of BICR-documented progressive disease. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Months | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) |
|---|---|---|
| Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) | NA (NA to NA) | 16.76 (12.22 to 25.10) |
TFFS by BICR is defined as the time from randomization to the first occurrence of: * documented radiographic disease progression per RECIST 1.1 as assessed by BICR; or * unacceptable toxicity leading to treatment discontinuation as assessed by the investigator. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. To qualify as an event, the toxicity must be from an intolerable AE (defined as any study drug-related AE that meets protocol guidance for treatment discontinuation, with the exception of alopecia); or death (due to any cause).
| Months | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) |
|---|---|---|
| Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR) | NA (NA to NA) | 13.93 (11.27 to 25.10) |
ORR is defined as the number of participants who achieved the best overall response (BOR) of CR or PR divided by the total number of participants randomized to each treatment arm. ORR per RECIST 1.1 as assessed by BICR.
| Percentage of Participants | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) |
|---|---|---|
| Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR | 69.4 (62.4 to 75.8) | 38.8 (29.1 to 49.2) |
DoR by BICR is defined as the time from the date that measurement criteria for complete response (CR) or partial response (PR) (whichever is first recorded) are first met by the BICR or investigator assessment, as applicable, until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Months | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) |
|---|---|---|
| Duration of Response (DoR) by BICR | NA (NA to NA) | 16.56 (10.41 to NA) |
Overall survival (OS) is defined as the time from randomization until death from any cause. If the participant is alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.
Results for this outcome have not been posted.
Progression-free survival 2 (PFS2) is defined as the time from randomization to disease progression (radiographic or symptomatic progression as determined by the investigator) on the next line of treatment or death from any cause in the absence of observed disease progression. If the participant is alive at the cutoff for analysis, and disease progression has not been observed, PFS2 data will be censored on the latest date of last progression-free assessment or start of the next line of treatment.
Results for this outcome have not been posted.
Comparative tolerability defined as a comparison of the proportion of time on treatment with high side effect bother as assessed by the FACT-GP5. The FACT-GP5 is a single question used to assess the overall bother of the treatment side effects. It is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bother from treatment side effects. Time with high side effect bother (i.e.) score of 3 or 4 is reported here and was derived as follows: cumulative amount of time, in weeks, during which a participant reports high side effect bother divided by the total duration of therapy (weeks), derived as (date of last study treatment dose - date of first study treatment dose + 1) divided by 7.
| Weeks | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) |
|---|---|---|
| Comparative Tolerability: Number of Weeks With High Side Effect Bother Based Score of 3 or 4 on the Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5) | 0.08 ± 0.169 | 0.24 ± 0.304 |
Results for this outcome have not been posted.
Collected over Baseline up to 39 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selpercatinib - Treatment A (TRT A) | 8/193 (4.1%) | 43/193 (22.3%) | 184/193 (95.3%) |
| Cabozantinib or Vandetanib - Treatment B (TRT B) | 10/97 (10.3%) | 27/97 (27.8%) | 96/97 (99%) |
| Event | Selpercatinib - Treatment A (TRT A) | Cabozantinib or Vandetanib - Treatment B (TRT B) |
|---|---|---|
| HypertensionVascular disorders | 2/193 | 4/97 |
| PancreatitisGastrointestinal disorders | 0/193 | 2/97 |
| PyrexiaGeneral disorders | 3/193 | 0/97 |
| PneumoniaInfections and infestations | 3/193 | 0/97 |
| Ovarian cystReproductive system and breast disorders | 1/78 | 0/30 |
| ColporrhaphySurgical and medical procedures | 1/78 | 0/30 |
| Urinary tract infectionInfections and infestations | 2/193 | 0/97 |
| PolycythaemiaBlood and lymphatic system disorders | 1/193 | 1/97 |
| Cardiac failureCardiac disorders | 0/193 | 1/97 |
| Myocardial infarctionCardiac disorders | 0/193 | 1/97 |
| Event | Selpercatinib - Treatment A (TRT A) | Cabozantinib or Vandetanib - Treatment B (TRT B) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 51/193 | 59/97 |
| HypertensionVascular disorders | 82/193 | 39/97 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 7/193 | 41/97 |
| Aspartate aminotransferase increasedInvestigations | 46/193 | 37/97 |
| Alanine aminotransferase increasedInvestigations | 51/193 | 33/97 |
| NauseaGastrointestinal disorders | 20/193 | 31/97 |
| Dry mouthGastrointestinal disorders | 61/193 | 10/97 |
| Weight decreasedInvestigations | 10/193 | 27/97 |
| Decreased appetiteMetabolism and nutrition disorders | 23/193 | 27/97 |
| Mucosal inflammationGeneral disorders | 14/193 | 25/97 |
All randomized participants, even if a participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.
| Age, Categorical(Participants) | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 143 | 72 | 215 |
| >=65 years | 49 | 26 | 75 |
| Sex: Female, Male(Participants) | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) | Total |
|---|---|---|---|
| Female | 78 | 30 | 108 |
| Male | 115 | 68 | 183 |
| Ethnicity (NIH/OMB)(Participants) | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 9 | 3 | 12 |
| Unknown or Not Reported | 181 | 94 | 275 |
| Race (NIH/OMB)(Participants) | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 43 | 24 | 67 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 7 |
| White | 116 | 52 | 168 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 29 | 20 | 49 |
| Region of Enrollment(Participants) | Selpercatinib (TRT A) | Cabozantinib or Vandetanib (TRT B) | Total |
|---|---|---|---|
| United States | 11 | 4 | 15 |
| Czechia | 6 | 0 | 6 |
| Japan | 5 | 1 | 6 |
| United Kingdom | 9 | 3 | 12 |
| India | 9 | 2 | 11 |
| Russia | 15 | 6 | 21 |
| Spain | 9 | 3 | 12 |
| Greece | 3 | 1 | 4 |
| Canada | 1 | 1 | 2 |
| Netherlands | 6 | 3 | 9 |
| South Korea | 10 | 2 | 12 |
| Belgium | 1 | 0 | 1 |
| China | 14 | 16 | 30 |
| Taiwan | 4 | 1 | 5 |
| Brazil | 20 | 13 | 33 |
| Poland | 15 | 10 | 25 |
| Italy | 14 | 6 | 20 |
| Israel | 1 | 0 | 1 |
| Australia | 9 | 2 | 11 |
| France | 24 | 18 | 42 |
| Germany | 7 | 6 | 13 |
Showing the first 100 of 143 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2020 to primary completion in May 2023, 39 months.
Results were first posted in Jun 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib